Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Carpenter Technology Corporation engages in the manufacture, fabrication, and distribution of specialty metals in the United States, Europe, the Asia Pacific, Mexico, Canada, and internationally. It operates in two segments, Specialty Alloys Operations and Performance Engineered Products. The company offers specialty alloys, including titanium alloys, powder metals, stainless steels, alloy steels, and tool steels, as well as additives, and metal powders and parts. It serves aerospace, defense, medical, transportation, energy, industrial, and consumer markets. The company was founded in 1889 and is headquartered in Philadelphia, Pennsylvania.

Carpenter Technology Corporation

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

PHILADELPHIA, AUG. 14, 2025 (GLOBE NEWSWIRE) -- CARPENTER TECHNOLOGY CORPORATION(NYSE: CRS) ANNOUNCED THAT ITS BOARD OF DIRECTORS HAS DECLARED A QUARTERLY CASH DIVIDEND OF$0.20PER SHARE OF COMMON STOCK, PAYABLESEPTEMBER 4, 2025, TO SHAREHOLDERS OF RECORD ONAUGUST 26, 2025. ABOUT CARPENTER TECHNOLOGY CARPENTER TECHNOLOGY CORPORATION IS A RECOGNIZED LEADER IN HIGH-PERFORMANCE SPECIALTY ALLOY MATERIALS AND PROCESS SOLUTIONS FOR CRITICAL APPLICATIONS IN THE AEROSPACE AND DEFENSE, MEDICAL, AND OTHER MARKETS.

CARPENTER TECHNOLOGY DECLARES QUARTERLY CASH DIVIDEND

PHILADELPHIA, AUG. 13, 2025 (GLOBE NEWSWIRE) -- CARPENTER TECHNOLOGY CORPORATION (NYSE: CRS) (THE COMPANY) TODAY ANNOUNCED THE EXECUTION OF SUCCESSION PLANS FOR THE BOARD OF DIRECTORS. CARPENTER TECHNOLOGY'S BOARD OF DIRECTORS HAS UNANIMOUSLY ELECTED TONY R.

CARPENTER TECHNOLOGY'S BOARD OF DIRECTORS ELECTS TONY THENE AS CHAIRMAN AND CEO

DELIVERED RECORD QUARTERLY OPERATING INCOME IN FOURTH QUARTER GENERATED RECORD ADJUSTED FREE CASH FLOW IN FOURTH QUARTER COMPLETED MOST PROFITABLE YEAR IN COMPANY HISTORY FISCAL YEAR 2026 OUTLOOK 26% TO 33% HIGHER THAN RECORD FISCAL YEAR 2025 PHILADELPHIA, JULY 31, 2025 (GLOBE NEWSWIRE) -- CARPENTER TECHNOLOGY CORPORATION (NYSE: CRS) (THE COMPANY) TODAY ANNOUNCED FINANCIAL RESULTS FOR THE FISCAL FOURTH QUARTER AND YEAR ENDED JUNE30, 2025. FOR THE QUARTER, THE COMPANY REPORTED OPERATING INCOME OF $151.4 MILLION, AND EARNINGS PER DILUTED SHARE OF $2.21.

CARPENTER TECHNOLOGY REPORTS FOURTH QUARTER AND FISCAL YEAR 2025 RESULTS

PHILADELPHIA, JULY 07, 2025 (GLOBE NEWSWIRE) -- CARPENTER TECHNOLOGY CORPORATION(NYSE: CRS) PLANS TO HOST A CONFERENCE CALL AND WEBCAST ON THURSDAY, JULY 31, 2025 AT 10:00 A.M. ET TO DISCUSS THE RESULTS OF OPERATIONS FOR THE FOURTH QUARTER OF FISCAL YEAR 2025, ENDED JUNE 30, 2025.

CARPENTER TECHNOLOGY ANNOUNCES CONFERENCE CALL AND WEBCAST

WATERTOWN, MASS., JUNE 02, 2025 (GLOBE NEWSWIRE) -- LYRA THERAPEUTICS, INC. (NASDAQ: LYRA) (LYRA OR THE COMPANY), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY DEVELOPING LONG-ACTING, ANTI-INFLAMMATORY SINONASAL IMPLANTS FOR THE TREATMENT OF CHRONIC RHINOSINUSITIS (CRS), TODAY ANNOUNCED POSITIVE RESULTS FROM THE ENLIGHTEN 2 PHASE 3 CLINICAL TRIAL OF LYR-210 IN ADULT PATIENTS WITH CRS. THE ENLIGHTEN 2 TRIAL MET ITS PRIMARY ENDPOINT, WITH LYR-210 DEMONSTRATING STATISTICALLY SIGNIFICANT IMPROVEMENT COMPARED TO SHAM CONTROL IN A COMPOSITE OF THE THREE CARDINAL SYMPTOMS (3CS) OF CRS (NASAL OBSTRUCTION, NASAL DISCHARGE, FACIAL PAIN/PRESSURE) AT WEEK 24 (-1.13; P=0.0078) IN PATIENTS WITHOUT NASAL POLYPS.

LYRA THERAPEUTICS REPORTS POSITIVE RESULTS FROM THE ENLIGHTEN 2 PHASE 3 TRIAL OF LYR-210 ACHIEVING STATISTICALLY SIGNIFICANT RESULTS FOR PRIMARY AND KEY SECONDARY ENDPOINTS IN THE TREATMENT OF CHRONIC RHINOSINUSITIS (CRS)

 PHASE 3 RESULTS FROM ENLIGHTEN 2 PIVOTAL PHASE 3 TRIAL OF LYR 210 IN CHRONIC RHINOSINUSITIS (CRS) EXPECTED IN Q2 2025   PHASE 3 RESULTS FROM ENLIGHTEN 2 PIVOTAL PHASE 3 TRIAL OF LYR 210 IN CHRONIC RHINOSINUSITIS (CRS) EXPECTED IN Q2 2025 

LYRA THERAPEUTICS REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

DELIVERED MOST PROFITABLE QUARTER IN COMPANY HISTORY EXCEEDED THIRD QUARTER OPERATING INCOME GUIDANCE EXPANDED OPERATING MARGINS IN SPECIALTY ALLOYS OPERATIONS SEGMENT GENERATED POSITIVE ADJUSTED FREE CASH FLOW REPURCHASED SHARES AGAINST AUTHORIZED SHARE REPURCHASE PROGRAM RAISING FISCAL YEAR 2025 GUIDANCE PHILADELPHIA, APRIL 24, 2025 (GLOBE NEWSWIRE) -- CARPENTER TECHNOLOGY CORPORATION (NYSE: CRS) (THE COMPANY) TODAY ANNOUNCED FINANCIAL RESULTS FOR THE FISCAL THIRD QUARTER ENDED MARCH31, 2025. FOR THE QUARTER, THE COMPANY REPORTED OPERATING INCOME OF $137.8 MILLION, AND EARNINGS PER DILUTED SHARE OF $1.88.

CARPENTER TECHNOLOGY REPORTS THIRD QUARTER FISCAL YEAR 2025 RESULTS

PHILADELPHIA, APRIL 10, 2025 (GLOBE NEWSWIRE) -- CARPENTER TECHNOLOGY CORPORATION(NYSE: CRS) ANNOUNCED THAT ITS BOARD OF DIRECTORS HAS DECLARED A QUARTERLY CASH DIVIDEND OF$0.20PER SHARE OF COMMON STOCK, PAYABLEJUNE 5, 2025, TO SHAREHOLDERS OF RECORD ONAPRIL 22, 2025.

PHILADELPHIA, APRIL 04, 2025 (GLOBE NEWSWIRE) -- CARPENTER TECHNOLOGY CORPORATION(NYSE: CRS) PLANS TO HOST A CONFERENCE CALL AND WEBCAST ON THURSDAY, APRIL 24, 2025 AT 10:00 A.M. ET TO DISCUSS THE RESULTS OF OPERATIONS FOR THE THIRD QUARTER OF FISCAL YEAR 2025, ENDED MARCH 31, 2025. THE CALL AND WEBCAST WILL FOLLOW THE RELEASE OF THIRD QUARTER FISCAL 2025 FINANCIAL RESULTS BEFORE THE MARKET OPENS ON THURSDAY, APRIL 24, 2025.

TORONTO, ONTARIO--(NEWSFILE CORP. - APRIL 3, 2025) - DELPHX CAPITAL MARKETS INC. (TSXV: DELX) (OTCQB: DPXCF) ("DELPHX" OR "THE COMPANY"), A LEADER IN THE DEVELOPMENT OF NEW CLASSES OF STRUCTURED PRODUCTS FOR THE FIXED INCOME MARKET, WISHES TO UPDATE INVESTORS ON THE ADVANCEMENTS IN ITS CREDIT RATING SECURITY ("CRS") PROGRAM. AS THE MERITS OF THE CRS SOLUTION BECOMES MORE WIDELY RECOGNIZED, THE COMPANY HAS BEEN ABLE TO EXPAND BOTH POTENTIAL BUYERS AND SELLERS OF CRS TO NOW INCLUDE THREE LEADING HEDGE FUNDS AND TWO INSURANCE COMPANIES, WHO TOGETHER ARE NEGOTIATING TERMS TO THE FIRST GROUPINGS OF BONDS WHICH WILL BE REFERENCED IN THESE FIRST ISSUANCES.

DELPHX CAPITAL MARKETS PROVIDES UPDATE ON CRS PROGRAM AND EXPANDS BROKER-DEALER SERVICES TO INCLUDE PRIVATE PLACEMENTS FOR MID-MARKET COMPANIES

HOLLYWOOD, FLA., MARCH 21, 2025 (GLOBE NEWSWIRE) -- NV5, A PROVIDER OF TECHNOLOGY, CERTIFICATION, AND CONSULTING SOLUTIONS, ANNOUNCED TODAY THAT IT HAS COMPLETED THE ACQUISITION OF CRS SURVEY PLLC (CRS SURVEY), A PROVIDER OF LAND SURVEYING AND MAPPING SERVICES FOR TRANSPORTATION INFRASTRUCTURE AND LAND DEVELOPMENT TO EXPAND AND SUPPORT NV5'S EXISTING OPERATION IN NORTH CAROLINA. CRS SURVEY SPECIALIZES IN CONVENTIONAL AND GEOSPATIAL AERIAL SURVEYS TO SUPPORT ROADWAY AND BRIDGE MAINTENANCE AND IMPROVEMENTS.

NV5 ACQUIRES CRS SURVEY; STRENGTHENS NORTH CAROLINA INFRASTRUCTURE CAPABILITIES

PARATEK WILL ACCELERATE ACCESS FOR XHANCE BEYOND SPECIALISTS TO PRIMARY CARE PROVIDERS MAXIMIZING THE RECENT LABEL EXPANSION FOR CRS IN A ~10  MILLION  PATIENT MARKET ACQUISITION ADVANCES PARATEK'S VISION TO BECOME A MULTI-PRODUCT COMPANY FOCUSED ON INNOVATIVE SPECIALTY THERAPIES TOTAL TRANSACTION VALUE OF UP TO ~$330 MILLION POTENTIAL CONSIDERATION OF UP TO $14 PER SHARE, INCLUDING UPFRONT CONSIDERATION OF $9 PER SHARE, REPRESENTING A 50% PREMIUM TO OPTINOSE'S CLOSING TRADING PRICE ON MARCH 19, 2025 BOSTON AND YARDLEY, PA., MARCH 19, 2025 (GLOBE NEWSWIRE) -- PARATEK PHARMACEUTICALS AND OPTINOSE, INC. (NASDAQ:OPTN) TODAY ANNOUNCED THEY HAVE ENTERED INTO A DEFINITIVE MERGER AGREEMENT UNDER WHICH PARATEK WILL ACQUIRE OPTINOSE, INCLUDING ITS APPROVED PRODUCT XHANCE  (FLUTICASONE PROPIONATE).

Carpenter Technology Corporation

CRS

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Carpenter Technology Corporation

CRS.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

CRS